Funding Opportunity Overview
Investigating the Effects of Addictive Substances on Brain Developmental Trajectories Using Innovative Scalable Methods for Quantification of Cell Identity, Lineage and Connectivity (R01 - Clinical Trial Not Allowed) is a Discretionary grant funded by National Institutes of Health. It's award amount is up to $700,000. It is categorized in Health. The grants is open to all (government, organization, and/or individual) entities. The application deadline (close date) to apply is 2023-02-02 (-2 days left).
The following table summarizes the Investigating the Effects of Addictive Substances on Brain Developmental Trajectories Using Innovative Scalable Methods for Quantification of Cell Identity, Lineage and Connectivity (R01 - Clinical Trial Not Allowed) opportunity.
| Opportunity Number | RFA-DA-23-036 |
|---|---|
| Opportunity Title | Investigating the Effects of Addictive Substances on Brain Developmental Trajectories Using Innovative Scalable Methods for Quantification of Cell Identity, Lineage and Connectivity (R01 - Clinical Trial Not Allowed) |
| Opportunity Category | Discretionary |
| Funding Instrument Type | Grant |
| Post Date | November 8, 2022 (Tuesday) |
| Last Updated Date | November 8, 2022 (Tuesday) |
| Close Date | February 2, 2023 (Thursday) |
| Award Amount | Up to $700,000 |
Detailed Funding Description
This Funding Opportunity Announcement (FOA) will support projects that investigate the effects of addictive substances on developmental trajectories of molecularly-defined CNS cells and circuits. Emphasis is on carrying out systematic and highly granular quantitative characterizations of the impact of in utero and/or postnatal substance exposure on the numbers, spatial distribution and connectivity of molecularly-defined cells, across whole brains or within distributed circuits of clinical relevance.
The ultimate goals of the program are to identify critical developmental windows and cellular mechanisms mediating the protracted developmental impact of addictive substances, and will inform clinical practice, by complementing the data from human longitudinal neuroimaging studies such as the ABCD study.
Dates and Awards Details
The following table shows the dates and awards information in detail for Investigating the Effects of Addictive Substances on Brain Developmental Trajectories Using Innovative Scalable Methods for Quantification of Cell Identity, Lineage and Connectivity (R01 - Clinical Trial Not Allowed) federal grants. It posted on 2022-11-08 and will be closed on 2023-02-02.
| Agency Name | National Institutes of Health | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Important Dates |
| ||||||||
| Awards Detail |
| ||||||||
| Cost Sharing or Matching Requirement | No | ||||||||
| Additional Information | https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-23-036.html | ||||||||
| Additional Information URL | http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-23-036.html |
CFDA Numbers
The next CFDA (Catalog of Federal Domestic Assistance) numbers are associated to this federal grant.
- 93.279 - Drug Abuse and Addiction Research Programs
Categories of Funding Activities
- Education
- Health
- No Additional Explanation Reported
Funding Eligibility
Eligible Applicants:
- State governments
- Additional Information: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Grantor Contact Information
| Grantor Detail | NIH Grants Information grantsinfo@nih.gov |
|---|---|
| grantsinfo@nih.gov (See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.) |